Alnylam Pharmaceuticals
ALNY
$309.66
-3.27%
Alnylam Pharmaceuticals is a biotechnology company that pioneers RNA interference (RNAi) therapeutics, a platform for silencing disease-causing genes, with a portfolio of commercial drugs for rare diseases like hATTR amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1. The company is the clear commercial and scientific leader in the RNAi therapeutic space, having transitioned from a platform innovator to a fully integrated commercial-stage biopharma. The current investor narrative revolves around the company's transition to sustainable profitability, driven by strong revenue growth from its commercial products, while also debating the valuation impact of its maturing growth profile and the pipeline's ability to deliver the next wave of commercial catalysts.…
ALNY
Alnylam Pharmaceuticals
$309.66
Investment Opinion: Should I buy ALNY Today?
Rating: Hold. The core thesis is that ALNY presents a compelling but high-risk growth story where deteriorating technicals and a rich trailing valuation offset fundamentally strong commercial execution, warranting a wait-and-see approach. This aligns with the analyst consensus 'Buy' but acknowledges the stock's severe recent underperformance.
Supporting evidence for this cautious stance includes the company's robust 84.95% YoY revenue growth and transition to profitability with an 8.45% net margin. The forward P/E of 21.94x is reasonable if $19.08 in forward EPS is achieved, implying significant earnings growth. However, this is counterbalanced by a severe technical downtrend (-35.71% over 6 months), a lofty trailing P/E of 166x, and a high short ratio of 4.49 signaling skepticism.
The thesis would upgrade to a Buy if the stock demonstrates sustained price stabilization above key resistance (e.g., $340-$350), confirming the downtrend has broken, or if forward earnings estimates are meaningfully raised post-strong quarterly results. It would downgrade to a Sell if revenue growth decelerates sharply below 50% YoY, the stock breaks below its 52-week low of $228, or pipeline setbacks emerge. Currently, the stock appears fairly valued on a forward basis but overvalued on a trailing basis, with the market pricing in near-perfect execution.
Sign up to view all
ALNY 12-Month Price Forecast
ALNY is a battleground stock caught between powerful fundamental improvement and severe technical deterioration. The commercial story is compelling, with revenue growth and profitability inflecting sharply. However, the market is demanding proof that this growth is sustainable before rewarding the stock, leading to a painful derating. The forward P/E of 22x offers a reasonable entry point for patient investors, but the broken chart warns of further downside risk. The stance would upgrade to bullish on a confirmed technical reversal above $350, supported by another quarter of strong execution. It would turn bearish if the stock breaks below $228, signaling a failure of the fundamental thesis.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alnylam Pharmaceuticals's 12-month outlook, with a consensus price target around $402.56 and implied upside of +30.0% versus the current price.
Average Target
$402.56
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$248 - $403
Analyst target range
Analyst coverage for ALNY is moderate with 9 analysts providing estimates, and recent institutional ratings show a strong bullish bias, with 7 out of the last 10 actions being 'Buy' recommendations, including a recent upgrade from Freedom Capital Markets. The consensus recommendation is Buy, and while a specific average target price is not provided in the data, the estimated revenue and EPS averages for future periods indicate analysts are modeling continued strong growth, with estimated revenue averaging $11.35 billion and EPS averaging $19.08, which would support a significantly higher valuation if achieved. The target range implied by the estimates is wide, with estimated revenue spanning from $10.46 billion to $13.36 billion and EPS from $17.12 to $23.46, reflecting high uncertainty around the commercial execution and peak sales potential of Alnylam's pipeline. The high-end targets likely assume successful pipeline readouts, market expansion for current products, and sustained high margins, while the low-end may factor in competitive threats, pricing pressure, or clinical setbacks. The recent mix of reiterated Buys and one downgrade to Hold (Jefferies) signals generally strong conviction but also some caution as the stock has corrected, with the wide spread in estimates underscoring the binary nature of biotech outcomes and the importance of upcoming catalysts.
Bulls vs Bears: ALNY Investment Factors
The investment debate for ALNY is a classic clash between deteriorating price action and strengthening fundamentals. The bear case, led by a severe 6-month downtrend and a sky-high trailing P/E, currently has stronger near-term evidence as the market votes with its feet. However, the bull case is supported by a powerful, data-driven inflection in revenue (85% YoY growth) and profitability (Q4 net income of $186M). The single most important tension is whether the company's explosive commercial execution can overcome the market's skepticism and valuation compression before a negative feedback loop sets in. The resolution hinges on the sustainability of its 85% growth rate into future quarters.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue surged 84.95% year-over-year to $1.097 billion, demonstrating the successful commercial scaling of its RNAi therapeutics. This multi-quarter acceleration, from $594M in Q1 to $1.249B in Q3, confirms a powerful transition to a high-growth commercial entity.
- Profitability Inflection Achieved: The company has turned decisively profitable, with Q4 2025 net income of $186.4 million and a trailing net margin of 8.45%. This marks a critical milestone from consistent net losses in early 2025, validating the business model and providing a foundation for sustainable earnings growth.
- Strong Analyst Conviction: Analyst sentiment is strongly bullish, with 7 of the last 10 institutional actions being 'Buy' recommendations. The consensus forward EPS estimate of $19.08 implies massive earnings growth, supporting a significantly higher valuation if the company executes on its commercial and pipeline plans.
- Robust Financial Health: The company generates substantial free cash flow ($465.4M TTM) and maintains a strong current ratio of 2.76, providing ample liquidity for R&D and operations. An impressive ROE of 39.76% indicates efficient use of capital post-profitability.
Bearish
- Severe Technical Downtrend: The stock price has collapsed 35.71% over the past six months and trades at just 62.5% of its 52-week range, near its lows. This persistent negative momentum and underperformance versus the SPY (-42.6% over 6 months) reflect deep investor skepticism and a broken chart pattern.
- Extremely High Trailing Valuation: A trailing P/E of 166.04x is astronomically high, even for biotech, indicating the stock is priced for perfection on future earnings. This premium leaves the stock vulnerable to multiple compression if growth decelerates or if there are any commercial or clinical missteps.
- Elevated Financial Leverage: A debt-to-equity ratio of 1.62 signifies a leveraged balance sheet. While manageable given current cash flow, this increases financial risk and means a significant portion of the high ROE is driven by leverage, not purely operational excellence.
- High Short Interest: A short ratio of 4.49 indicates substantial bearish betting against the stock. This creates headline risk from short squeezes but, more importantly, reflects a cohort of sophisticated investors who believe the recent growth and profitability are unsustainable.
ALNY Technical Analysis
The stock is in a pronounced downtrend, having declined 35.71% over the past six months and 13.81% over the last three months, significantly underperforming the broader market. With a current price of $309.66, the stock is trading at approximately 62.5% of its 52-week range ($228.28 to $495.55), indicating it is much closer to its yearly lows than its highs, which may suggest a value opportunity but also reflects persistent negative momentum and investor skepticism. Recent short-term momentum shows a modest 1-month decline of 1.63%, which, while still negative, is a deceleration from the steeper 3-month drop, hinting at potential stabilization or consolidation after the severe sell-off, though the stock's relative strength versus the SPY remains deeply negative across all measured periods. Key technical support is clearly defined at the 52-week low of $228.28, while resistance lies at the 52-week high of $495.55. A sustained breakdown below the $228 support would signal a continuation of the bearish trend and likely trigger further selling, whereas a recovery above the recent local highs near $340-$350 would be necessary to suggest a meaningful reversal is underway. The stock exhibits a beta of 0.383, indicating it has been significantly less volatile than the market during this downtrend, which is unusual for a biotech but may reflect its transition to a more commercial, cash-generative profile; however, this low beta is juxtaposed against a substantial 37.57% maximum drawdown, highlighting the stock's idiosyncratic, event-driven risk profile.
Beta
0.38
0.38x market volatility
Max Drawdown
-37.6%
Largest decline past year
52-Week Range
$228-$496
Price range past year
Annual Return
+32.0%
Cumulative gain past year
| Period | ALNY Return | S&P 500 |
|---|---|---|
| 1m | -1.6% | +9.5% |
| 3m | -13.8% | +2.7% |
| 6m | -35.7% | +5.8% |
| 1y | +32.0% | +34.9% |
| ytd | -22.6% | +4.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALNY Fundamental Analysis
Revenue growth is robust and accelerating, with Q4 2025 revenue of $1.097 billion representing a massive 84.95% year-over-year increase, building on the strong $1.249 billion reported in Q3 2025. This multi-quarter growth trend is driven by the successful commercial launches of products like Amvuttra and Givlaari, with segment data showing Givlaari contributing $160.67 million in a recent period, indicating a diversified and growing product portfolio. The revenue trajectory solidifies Alnylam's transition from a research-focused entity to a commercial growth story, though investors will scrutinize future quarters for sustainability of this exceptional growth rate. Profitability has turned decisively positive, with Q4 2025 net income of $186.419 million and a trailing twelve-month net margin of 8.45%, marking a critical inflection point for the company. Gross margins are exceptionally high at 81.77%, typical for a commercial-stage biotech with proprietary products, and operating margins have improved to 13.51%, demonstrating operating leverage as revenue scales. The quarterly progression from net losses in early 2025 (Q1: -$57.5M, Q2: -$66.3M) to substantial profits in Q3 ($251.1M) and Q4 confirms the company's path to sustainable profitability, a key milestone for the investment thesis. The balance sheet shows a debt-to-equity ratio of 1.62, indicating a leveraged but manageable capital structure for a growing biotech. Financial health is supported by strong cash generation, with free cash flow over the trailing twelve months at $465.383 million and a current ratio of 2.76, providing ample liquidity. The return on equity of 39.76% is impressive and reflects efficient use of shareholder capital post-profitability, though the high debt level means a significant portion of this ROE is driven by financial leverage, which investors must monitor alongside the company's ongoing R&D investments.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.84%
YoY Comparison
Gross Margin
+0.75%
Latest Quarter
Free Cash Flow
$465383000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALNY Overvalued?
Given that Alnylam reported positive net income of $186.419 million for Q4 2025, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is extremely high at 166.04x, reflecting the market pricing the stock on its recent transition to profitability, while the forward PE is a much lower 21.94x, indicating the market expects a dramatic surge in earnings over the next year as profitability normalizes from its current nascent stage. Compared to typical biotechnology industry averages, Alnylam's trailing PE of 166x represents a significant premium, though the forward PE of 22x is more in line with profitable growth biotechs. The substantial discount of the forward PE relative to the trailing figure (an 87% drop) underscores the market's expectation of explosive earnings growth, pricing in the successful scaling of its commercial portfolio; whether this premium is justified hinges entirely on the company's ability to meet these lofty earnings expectations and sustain its growth trajectory. Historically, the stock's own valuation has been volatile due to its previous lack of profits, but the current trailing PE of 166x sits well below the extreme historical highs seen in prior quarters (e.g., 256x in Q3 2025). This suggests the recent price decline has compressed the valuation multiple despite improving fundamentals, potentially creating an entry point if the earnings growth materializes as forecasted, though it remains elevated compared to its own history when it was deeply unprofitable.
PE
166.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -456x~71x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
92.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the company's ability to sustain its explosive growth trajectory to justify its valuation. While profitability has turned positive, the trailing P/E of 166x is extraordinarily high and dependent on forward earnings estimates of ~$19.08 materializing. A debt-to-equity ratio of 1.62 introduces financial leverage risk, and the wide range in analyst revenue estimates ($10.46B to $13.36B) highlights uncertainty in commercial execution. Any deceleration in the 85% YoY revenue growth or margin pressure from competition could trigger a severe derating.
Market & Competitive Risks are pronounced. The stock trades at a significant premium to industry averages on a trailing basis, making it highly susceptible to valuation compression in a rising rate environment or sector rotation away from growth. Its low beta of 0.383 is deceptive; the 37.57% maximum drawdown reveals high idiosyncratic, event-driven volatility typical of biotech. As the RNAi pioneer, it faces the perpetual risk of competitive disruption from newer genetic medicine platforms, and its rare disease focus exposes it to payer reimbursement pressures.
Worst-Case Scenario involves a combination of commercial growth deceleration, a pipeline clinical failure, and a broader biotech bear market. This could lead to a cascade of analyst downgrades and multiple compression. The realistic downside would be a retest and break below the 52-week low of $228.28, representing a potential loss of approximately -26% from the current price of $309.66. In an extreme adverse scenario where profitability falters, the stock could fall towards its book value, implying a far steeper decline given its high P/B ratio of 66x.
FAQ
The key risks are, in order of severity: 1) Valuation & Execution Risk: The high trailing P/E of 166x leaves no room for error; any growth slowdown could cause a severe derating. 2) Commercial/Competitive Risk: Sustaining 85% revenue growth is challenging, and new competing therapies could erode market share for its flagship products. 3) Pipeline & Clinical Risk: Future growth depends on clinical success, and setbacks would damage the long-term thesis. 4) Financial Risk: A debt-to-equity ratio of 1.62 introduces leverage, and the stock's high short interest (ratio 4.49) contributes to volatility and headline risk.
Our 12-month forecast outlines three scenarios. The Base Case (50% probability) sees the stock trading between $330 and $380 as the company delivers on current analyst estimates for ~$19 EPS, justifying its forward P/E. The Bull Case (30% probability) targets $450-$495, driven by outperforming growth and positive pipeline news. The Bear Case (20% probability) warns of a drop to $228-$280 if growth decelerates or clinical setbacks occur. The Base Case is most likely, assuming the company executes in line with expectations but continues to grapple with investor skepticism from its recent downturn.
ALNY's valuation presents a paradox: it is dramatically overvalued on a trailing basis (P/E of 166x) but appears more reasonably valued on a forward basis (P/E of 22x). This discrepancy shows the market is pricing in explosive earnings growth from its recent profitability inflection. Compared to profitable biotech peers, a forward P/E in the low 20s is not excessive for a company growing revenue at 85%. However, the valuation is entirely dependent on the company meeting lofty future earnings estimates. Therefore, it is fairly valued only if you have high confidence in its forward guidance; otherwise, the trailing multiple suggests it is expensive.
ALNY is a high-risk, high-reward investment that may be a good buy for aggressive growth investors comfortable with biotech volatility. The forward P/E of 22x is reasonable if the company hits its estimated EPS of $19.08, implying significant upside from current earnings. However, the stock is in a severe downtrend (-35.7% over 6 months) and carries a lofty trailing P/E of 166x, reflecting extreme skepticism. The biggest risk is a growth deceleration that triggers further multiple compression. It is a good buy only for those who believe the 85% YoY revenue growth is sustainable and are willing to endure potential near-term volatility.
ALNY is unequivocally a long-term investment, with a suggested minimum holding period of 3-5 years. Its value is tied to the multi-year commercialization of its current products and the development of its pipeline, not short-term trading catalysts. The stock's high volatility (37.57% max drawdown) and event-driven nature make it unsuitable for short-term traders without a high conviction in near-term clinical or commercial catalysts. Long-term investors can potentially benefit from the scaling of its RNAi platform, but must be prepared for significant price swings along the way.
